<cite id="uufuy"><noscript id="uufuy"></noscript></cite>
    <rp id="uufuy"></rp>

    OUR TEAM

    Our leadership team possesses rich and diverse industry knowledge, a passion for science and a shared commitment to help transform lives.

    Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.

    • Leonard S. Schleifer, MD, PhD: Founder, President & Chief Executive Officer

      Leonard S. Schleifer, MD, PhD

    • George D. Yancopoulos, MD, PhD: Founding Scientist, President & Chief Scientific Officer

      George D. Yancopoulos, MD, PhD

    • Founder, President & Chief Executive Officer

      Leonard S. Schleifer, MD, PhD, founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and seven FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.

    • Founding Scientist, President & Chief Scientific Officer

      George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s seven FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene? and VelocImmune?. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.


    • Hanne Bak, PhD: Senior Vice President, Preclinical Manufacturing & Process Development

      Hanne Bak, PhD


    • Aris Baras, MD: Senior Vice President, Regeneron Genetics Center

      Aris Baras, MD


    • Ned Braunstein, MD: Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

      Ned Braunstein, MD

    • Senior Vice President, Preclinical Manufacturing & Process Development

      Hanne Bak, PhD, joined Regeneron in 2004 and serves as the Senior Vice President, Preclinical Manufacturing & Process Development (PMPD). Dr. Bak started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and subsequently held roles of increasing responsibility moving up to Vice President. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).

    • Senior Vice President, Regeneron Genetics Center

      Aris Baras, MD, joined Regeneron in 2011. He serves as the Senior Vice President, Regeneron Genetics Center. Previously, Dr. Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MD and MBA from Duke University.

    • Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

      Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory A?airs, Pharmacovigilance and Risk Management. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory A?airs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.


    • Gerald Carreau: Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

      Gerald Carreau


    • Scott Carver, PhD: Senior Vice President, Manufacturing and Process Sciences

      Scott Carver, PhD


    • Thomas Daly, PhD: Senior Vice President, Preclinical Development & Protein Chemistry

      Thomas Daly, PhD

    • Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

      Gerald (Gerry) Carreau joined Regeneron in 2008. He is the Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Mr. Carreau was previously Vice President, Commercial Scale Manufacturing and Manufacturing Technology.?Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.

    • Senior Vice President, Manufacturing and Process Sciences

      Scott Carver, PhD, joined Regeneron in 1998 and serves as the Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing, and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.

    • Senior Vice President, Preclinical Development & Protein Chemistry

      Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in Biochemistry from Rice University and his BS in biochemistry from Hofstra University.


    • Robert E. Landry: Executive Vice President, Finance and Chief Financial Officer

      Robert E. Landry


    • Joseph J. LaRosa: Executive Vice President, General Counsel and Secretary

      Joseph J. LaRosa


    • Beth F. Levine: Senior Vice President, Associate General Counsel, Chief Compliance Officer

      Beth F. Levine

    • Executive Vice President, Finance and Chief Financial Officer

      Robert E. Landry joined the company in 2013?and serves as Executive Vice President, Finance and Chief Financial Officer. He previously held the position of?Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

    • Executive Vice President, General Counsel and Secretary

      Joseph J. LaRosa?joined Regeneron in 2011. He is currently Executive Vice President, General Counsel and Secretary; he previously held the position of Senior Vice President, General Counsel and Secretary.?Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Before coming to Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.

    • Senior Vice President, Associate General Counsel, Chief Compliance Officer

      Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance O?cer. Prior to joining Regeneron, Ms. Levine spent 13 years at P?zer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance O?cer. In the early days of her legal career, Ms. Levine was a litigation associate at the law ?rm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Levine received a BS from Cornell University and a JD from Fordham Law School.


    • Israel Lowy, MD, PhD: Senior Vice President, Translational Sciences and Oncology

      Israel Lowy, MD, PhD


    • Jay S. Markowitz, MD: Senior Vice President, Portfolio Management

      Jay S. Markowitz, MD


    • Marion McCourt: Senior Vice President, Commercial

      Marion McCourt

    • Senior Vice President, Translational Sciences and Oncology

      Israel (Izzy)?Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and serves as the Senior Vice President, Translational Sciences and Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr.?Lowy?was at Medarex for eight years. Previously, he was?Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. He is a licensed physician and has been board certified in internal medicine and infectious diseases. Dr.?Lowy?received his AB in Biochemical Sciences from?Princeton University and?his?MD-PhD?in Biochemistry and Molecular Biophysics from Columbia University.

    • Senior Vice President, Portfolio Management

      Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.

    • Senior Vice President, Commercial

      Marion McCourt joined Regeneron in 2018 and serves as Senior Vice President and Head of the Commercial organization. Prior to joining Regeneron, Marion was at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Marion began her career—and spent 12 years—at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.


    • Hala Mirza: Senior Vice President, Corporate Communications & Citizenship

      Hala Mirza


    • Andrew (Drew) Murphy, PhD: Executive Vice President, Research

      Andrew (Drew) Murphy, PhD


    • Sally A. Paull: Senior Vice President, Human Resources

      Sally A. Paull

    • Senior Vice President, Corporate Communications & Citizenship

      Hala Mirza joined Regeneron in 2014. She serves as the Senior Vice President, Corporate Communications and Citizenship?and leads corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, Ms. Mirza was the Vice President, Corporate Affairs for R&D and Strategy at Pfizer. Prior to joining Pfizer, Ms. Mirza was Managing Director at W20 group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.

    • Executive Vice President, Research

      Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Executive?Vice President of Research. Dr. Murphy is a co-inventor of several of Regeneron's key technologies — VelociGene??and VelocImmune??— and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

    • Senior Vice President, Human Resources

      Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources O?cer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources O?cer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.


    • Neil Stahl, PhD: Executive Vice President, Research & Development

      Neil Stahl, PhD


    • Daniel Van Plew: Executive Vice President & General Manager, Industrial Operations & Product Supply

      Daniel Van Plew


    • David Weinreich, MD, MBA: Senior Vice President, Global Clinical Development

      David Weinreich, MD, MBA

    • Executive Vice President, Research & Development

      Neil Stahl, PhD, has been Executive Vice President, Research and Development since January 2015. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. He joined the Company in 1991. Dr. Stahl received his PhD in Biochemistry from Brandeis University.

    • Executive Vice President & General Manager, Industrial Operations & Product Supply

      Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From April 2008 to December 2015, Mr. Van Plew served as Senior Vice President and General Manager, Industrial Operations and Product Supply. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in 2007. From 2006 until 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from The Pennsylvania State University and his MBA from Michigan State University.

    • Senior Vice President, Global Clinical Development

      David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. In 2017 he became the Senior Vice President, Global Clinical Development. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.


    • Brian Zambrowicz, PhD: Senior Vice President, Functional Genomics and Chief VelociGene? Operations

      Brian Zambrowicz, PhD

    • Senior Vice President, Functional Genomics and Chief VelociGene? Operations

      Brian Zambrowicz, PhD, joined Regeneron in 2015. He is Senior Vice President, Functional Genomics and Chief VelociGene? Operations. He previously held the role of Vice President, Functional Genomics and Chief VelociGene? Operations. Prior to Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

    • Leonard S. Schleifer, MD, PhD: Founder, President & Chief Executive Officer

      Leonard S. Schleifer, MD, PhD

    • Founder, President & Chief Executive Officer

      Leonard S. Schleifer, MD, PhD, founded the Company in 1988, has been a Director and its President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and seven FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.


    • George D. Yancopoulos, MD, PhD: Founding Scientist, President & Chief Scientific Officer

      George D. Yancopoulos, MD, PhD

    • Founding Scientist, President & Chief Scientific Officer

      George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s seven FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene? and VelocImmune?. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.


    • Hanne Bak, PhD: Senior Vice President, Preclinical Manufacturing & Process Development

      Hanne Bak, PhD

    • Senior Vice President, Preclinical Manufacturing & Process Development

      Hanne Bak, PhD, joined Regeneron in 2004 and serves as the Senior Vice President, Preclinical Manufacturing & Process Development (PMPD). Dr. Bak started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and subsequently held roles of increasing responsibility moving up to Vice President. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).


    • Aris Baras, MD: Senior Vice President, Regeneron Genetics Center

      Aris Baras, MD

    • Senior Vice President, Regeneron Genetics Center

      Aris Baras, MD, joined Regeneron in 2011. He serves as the Senior Vice President, Regeneron Genetics Center. Previously, Dr. Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MD and MBA from Duke University.


    • Ned Braunstein, MD: Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

      Ned Braunstein, MD

    • Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

      Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory A?airs, Pharmacovigilance and Risk Management. Prior to Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc, for nine years in positions of increasing responsibility in Clinical Research, Regulatory A?airs and Global Human Health. Dr. Braunstein received his BS in Medicine from Northwestern University in Evanston, Ill., and his MD from Northwestern University in Chicago.


    • Gerald Carreau: Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

      Gerald Carreau

    • Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

      Gerald (Gerry) Carreau joined Regeneron in 2008. He is the Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Mr. Carreau was previously Vice President, Commercial Scale Manufacturing and Manufacturing Technology.?Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.


    • Scott Carver, PhD: Senior Vice President, Manufacturing and Process Sciences

      Scott Carver, PhD

    • Senior Vice President, Manufacturing and Process Sciences

      Scott Carver, PhD, joined Regeneron in 1998 and serves as the Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing, and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.


    • Thomas Daly, PhD: Senior Vice President, Preclinical Development & Protein Chemistry

      Thomas Daly, PhD

    • Senior Vice President, Preclinical Development & Protein Chemistry

      Thomas Daly, PhD, joined Regeneron in 1996. He is Senior Vice President, Preclinical Development & Protein Chemistry. Dr. Daly was previously Vice President, Preclinical Development & Protein Chemistry and before that held positions of increasing responsibility in Protein Sciences. Prior to
      Regeneron, Dr. Daly served as a research scientist at Repligen Corporation. Dr. Daly received his PhD in Biochemistry from Rice University and his BS in biochemistry from Hofstra University.


    • Robert E. Landry: Executive Vice President, Finance and Chief Financial Officer

      Robert E. Landry

    • Executive Vice President, Finance and Chief Financial Officer

      Robert E. Landry joined the company in 2013?and serves as Executive Vice President, Finance and Chief Financial Officer. He previously held the position of?Senior Vice President, Finance and Chief Financial Officer. Previously, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Prior to this position, Mr. Landry held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.


    • Joseph J. LaRosa: Executive Vice President, General Counsel and Secretary

      Joseph J. LaRosa

    • Executive Vice President, General Counsel and Secretary

      Joseph J. LaRosa?joined Regeneron in 2011. He is currently Executive Vice President, General Counsel and Secretary; he previously held the position of Senior Vice President, General Counsel and Secretary.?Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and as a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Before coming to Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. Mr. LaRosa received his JD degree from New York University.


    • Beth F. Levine: Senior Vice President, Associate General Counsel, Chief Compliance Officer

      Beth F. Levine

    • Senior Vice President, Associate General Counsel, Chief Compliance Officer

      Beth Levine joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance O?cer. Prior to joining Regeneron, Ms. Levine spent 13 years at P?zer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance O?cer. In the early days of her legal career, Ms. Levine was a litigation associate at the law ?rm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Levine received a BS from Cornell University and a JD from Fordham Law School.


    • Israel Lowy, MD, PhD: Senior Vice President, Translational Sciences and Oncology

      Israel Lowy, MD, PhD

    • Senior Vice President, Translational Sciences and Oncology

      Israel (Izzy)?Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and serves as the Senior Vice President, Translational Sciences and Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr.?Lowy?was at Medarex for eight years. Previously, he was?Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. He is a licensed physician and has been board certified in internal medicine and infectious diseases. Dr.?Lowy?received his AB in Biochemical Sciences from?Princeton University and?his?MD-PhD?in Biochemistry and Molecular Biophysics from Columbia University.


    • Jay S. Markowitz, MD: Senior Vice President, Portfolio Management

      Jay S. Markowitz, MD

    • Senior Vice President, Portfolio Management

      Jay S. Markowitz, MD, joined Regeneron in 2017 as Senior Vice President, Portfolio Management. Dr. Markowitz was previously at Capital World Investors, where he was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine. Dr. Markowitz received his MD from Duke University and his BA from Columbia University.


    • Marion McCourt: Senior Vice President, Commercial

      Marion McCourt

    • Senior Vice President, Commercial

      Marion McCourt joined Regeneron in 2018 and serves as Senior Vice President and Head of the Commercial organization. Prior to joining Regeneron, Marion was at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Marion began her career—and spent 12 years—at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.


    • Hala Mirza: Senior Vice President, Corporate Communications & Citizenship

      Hala Mirza

    • Senior Vice President, Corporate Communications & Citizenship

      Hala Mirza joined Regeneron in 2014. She serves as the Senior Vice President, Corporate Communications and Citizenship?and leads corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, Ms. Mirza was the Vice President, Corporate Affairs for R&D and Strategy at Pfizer. Prior to joining Pfizer, Ms. Mirza was Managing Director at W20 group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.


    • Andrew (Drew) Murphy, PhD: Executive Vice President, Research

      Andrew (Drew) Murphy, PhD

    • Executive Vice President, Research

      Drew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics. He has led the Gene Discovery and Bioinformatics group and the Target Discovery group, and is now the Executive?Vice President of Research. Dr. Murphy is a co-inventor of several of Regeneron's key technologies — VelociGene??and VelocImmune??— and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.


    • Sally A. Paull: Senior Vice President, Human Resources

      Sally A. Paull

    • Senior Vice President, Human Resources

      Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. Ms. Paull was previously Executive Vice President, Chief Human Resources O?cer at Inova Health System. Prior to Inova, she was Senior Vice President, Chief Human Resources O?cer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.


    • Neil Stahl, PhD: Executive Vice President, Research & Development

      Neil Stahl, PhD

    • Executive Vice President, Research & Development

      Neil Stahl, PhD, has been Executive Vice President, Research and Development since January 2015. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. He joined the Company in 1991. Dr. Stahl received his PhD in Biochemistry from Brandeis University.


    • Daniel Van Plew: Executive Vice President & General Manager, Industrial Operations & Product Supply

      Daniel Van Plew

    • Executive Vice President & General Manager, Industrial Operations & Product Supply

      Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From April 2008 to December 2015, Mr. Van Plew served as Senior Vice President and General Manager, Industrial Operations and Product Supply. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in 2007. From 2006 until 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from The Pennsylvania State University and his MBA from Michigan State University.


    • David Weinreich, MD, MBA: Senior Vice President, Global Clinical Development

      David Weinreich, MD, MBA

    • Senior Vice President, Global Clinical Development

      David Weinreich, MD, joined Regeneron as Senior Vice President, Late Stage Clinical Development and Medical Affairs in 2016. In 2017 he became the Senior Vice President, Global Clinical Development. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Prior to Bayer, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his MD from Boston University School of Medicine, his MBA from the McDonough School of Business at Georgetown University and his BS in computer engineering from Columbia University.


    • Brian Zambrowicz, PhD: Senior Vice President, Functional Genomics and Chief VelociGene? Operations

      Brian Zambrowicz, PhD

    • Senior Vice President, Functional Genomics and Chief VelociGene? Operations

      Brian Zambrowicz, PhD, joined Regeneron in 2015. He is Senior Vice President, Functional Genomics and Chief VelociGene? Operations. He previously held the role of Vice President, Functional Genomics and Chief VelociGene? Operations. Prior to Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

    免费四虎库精品视倾